SynthesisBMC infectious diseases2026
Antimicrobial resistance in bloodstream infections in West Africa: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly and efficient management of bloodstream infections (BSIs) reduces the risk of complications and death. Therefore, it is crucial to identify antimicrobials with good activity against bacteria isolated from BSIs. This study aimed to determine the bacterial pathogens involved in BSIs, pooled antimicrobial resistance (AMR) rate, AMR phenotype rates, and the evolution of AMR over the years in West Africa.
methodsThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA 2020) were used, and the protocol for this review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database with the registration identification number (CRD420251064773). Keywords were used to conduct a systematic literature review of electronic databases such as Google Scholar, African Journals Online, PubMed, ResearchGate, Embase, and Scopus. Data analyses were conducted using Stata/MP 17.0, and a random-effects model was used to estimate pooled estimates.
resultsTwenty-three research articles, including samples collected between 2003 and 2022, were selected for this study. The prevalence of BSIs was 13.1% (95% CI: 12.8-13.3) (6,864 blood culture-positive out of the 52,566 patients screened for BSIs). A total of 4,992 bacteria were isolated, including 3,219 Gram-negative bacteria (GNB) and 1,773 Gram-positive bacteria (GPB). The pooled AMR rates of 20 antimicrobials were obtained, and the highest were for ampicillin [73% (95% CI: 66, 80)] and trimethoprim-sulfamethoxazole [72% (95% CI: 63, 80)]. The lowest pooled AMR rates were observed for the carbapenems [10% (95% CI: 1, 25)] and clindamycin [15% (95% CI: 6, 27)]. GNB were more resistant to ampicillin (P = 0.003) and amoxicillin-clavulanate (P = 0.002) than GPB, and the pooled prevalence of multidrug-resistant bacteria (MDR) was 53% (95% CI: 30, 75). There were significant upward trends for ciprofloxacin (P = 0.007), carbapenems (P = 0.010), ofloxacin (P = 0.013), and third-generation cephalosporins (3GCs) (P = 0.032) when comparing the pooled AMR rates of 2004-2013 to those of 2014-2022.
conclusionCarbapenems and clindamycin showed relatively low resistance rates, but high study heterogeneity and limited data warrant caution in their empiric use. Overall, the findings highlight the need to prioritize local antibiograms and strengthen antimicrobial stewardship to address rising AMR in West Africa. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.